Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$1.1B
49M shares
52-week range
$19.16 – $48.25
11% from low
Sector
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Exchange
NYSE
CS
Borrow rate
0.40%
Easy to borrow
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $262.8M | $276.2M | $253.2M | $298.8M | $313.8M | $354.0M | $388.5M | $441.3M |
| Cost of revenue | $89.9M | $93.2M | $85.4M | $101.3M | $111.3M | $124.8M | $139.8M | $170.9M |
| Gross profit | $173.0M | $183.0M | $167.8M | $197.5M | $202.5M | $229.2M | $248.8M | $270.5M |
| Gross margin | 65.8% | 66.3% | 66.3% | 66.1% | 64.5% | 64.7% | 64.0% | 61.3% |
| R&D | $23.1M | $23.0M | $24.2M | $35.5M | $38.9M | $28.7M | $28.5M | $31.0M |
| Operating income | $9.3M | $17.0M | $2.4M | $8.1M | $6.2M | $5.7M | $38.9M | $26.7M |
| EBITDA | $30.2M | $34.8M | $20.2M | $26.0M | $25.7M | $26.8M | $51.0M | $63.8M |
| Net income | −$3.8M | $1.7M | −$16.7M | −$14.8M | −$19.2M | −$30.7M | −$13.4M | $9.8M |
| Net margin | -1.4% | 0.6% | -6.6% | -5.0% | -6.1% | -8.7% | -3.4% | 2.2% |
| EPS (diluted) | -0.10 | 0.05 | -0.44 | -0.38 | -0.48 | -0.75 | -0.32 | 0.21 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $486M | $0.10 | $0.09–$0.10 | 5 |
| 2027 | $540M | $0.41 | $0.40–$0.42 | 5 |
| 2028 | $601M | $0.80 | $0.70–$0.97 | 4 |
| 2029 | $678M | $1.19 | $1.17–$1.21 | 2 |
Forward consensus · source: Financial Modeling Prep
Artivion Inc offers cardiac and vascular surgeons a suite of aortic-centric solutions. The company's products include Aortic Heart Valve, Mitral Heart Valve, Aortic Allograft, Pulmonary Human Heart Valve, Pulmonary Patch, and Surgical Adhesive among others. The company's has two reportable segments: Medical Devices and Preservation Services. The Medical Devices segment includes revenues from sales of aortic stent grafts, surgical sealants, On-X products, and other product revenues. The Preservation Services segment includes services revenues from the preservation of cardiac and vascular implantable human tissues. Company operates in North America, EMEA. LATAM, APAC. Maximum revenue is from North America.
www.artivion.comNo one on the platform currently holds AORT.
No tracked institution reports a position in AORT as of their last filing.
No one on the platform has traded AORT yet.
| $6.6B |
| — |
| INSPInspire Medical Systems, Inc. | $44.93 | -1.73% | $1.3B | — |
| ITGRInteger Holdings Corporation | $91.22 | -2.84% | $3.1B | — |
Source: Financial Modeling Prep · peers by sector/industry
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
Trading at 2.4× sales vs its 2.4× historical median P/S.
Fair value ≈ $22.41 · price $22.39 today
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.
$AORT (+1.2% pre) Artivion receives FDA approval for aortic dissection device https://ooc.bz/l/106461
View on StockTwits ↗$AORT Took a little longer than expected, but out with my 10%. On to the next!
View on StockTwits ↗$AORT Artivion max pain price falls to -1.0 https://www.macroaxis.com/stock-options/AORT/Artivion?utm_source=dlvr.it&utm_medium=stocktwits
View on StockTwits ↗$AORT RSI = 24 (extremely bullish) Institutional Ownership = 91% MACD = broke positive on short term charts Trending = just hit supporting 5-year chat. Very strong support line News: Acquisition on 18th mostly overlooked Easy buy here, entered at $21.17
View on StockTwits ↗$AORT Down 21% over the last 5 years. What an absolute gargabe stock.
View on StockTwits ↗$AORT Between AMDS, NEXUS, and future Arcevo LSA, Artivion is building a full toolbox for complex aortic arch repair across open, hybrid, and endovascular approaches. https://prismmarketview.com/artivion-bets-big-on-aortic-arch-locking-in-endospans-nexus-system/
View on StockTwits ↗$AORT Artivion has closed its acquisition of Endospan Ltd., bringing the NEXUS Aortic Arch System in‑house after FDA PMA approval and expanding its advanced aortic portfolio. https://prismmarketview.com/artivion-seals-endospan-deal-bringing-nexus-aortic-arch-system-fully-in-house/
View on StockTwits ↗Artivion Q1 Earnings Call Highlights $AORT https://www.marketbeat.com/instant-alerts/artivion-q1-earnings-call-highlights-2026-05-09/
View on StockTwits ↗Premarket Losers: $FWRD $KDK $AIM $BTBD $AORT Download this screener: https://stockanalysis.com/markets/premarket/losers/?ref=saveontrading
View on StockTwits ↗$AORT Q1 '26 Earnings Results & Recap • Reported GAAP EPS of $0.03 up 400.00% YoY • Reported revenue of $116.34M up 17.54% YoY • Artivion lowered its full year 2026 revenue expectations to $480M to $496M, representing 7% to 11% constant currency growth, and adjusted EBITDA to $100M to $107M, reflecting 12% to 20% growth.
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.